CGRP inhibitors for migraine prophylaxis: a safety review

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

(2020) Messoud Ashina et al.   CEPHALALGIA

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

(2020) Stewart J Tepper et al.   CEPHALALGIA

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and safety of eptinezumab in patients with chronic migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice

(2020) Inge A. Mulder et al.   ANNALS OF NEUROLOGY

The fifth cranial nerve in headaches

(2020) J. C. A. Edvinsson et al.   JOURNAL OF HEADACHE AND PAIN

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans

(2020) Tessa de Vries et al.   PHARMACOLOGY & THERAPEUTICS

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?

(2019) Valentina Favoni et al.   JOURNAL OF HEADACHE AND PAIN

CGRP and the Trigeminal System in Migraine

(2019) Smriti Iyengar et al.   HEADACHE

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

(2019) Messoud Ashina et al.   CEPHALALGIA

Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries

(2019) Eloísa Rubio-Beltrán et al.   CEPHALALGIA

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

(2019) Robert Croop et al.   LANCET

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

(2019) Richard B. Lipton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fremanezumab for the preventive treatment of migraine in adults

(2019) Luana Lionetto et al.   Expert Review of Clinical Pharmacology

Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries

(2019) Eloísa Rubio-Beltran et al.   CEPHALALGIA

Targeting calcitonin gene-related peptide: a new era in migraine therapy

(2019) Andrew Charles et al.   LANCET

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

(2018) Christophe Depre et al.   HEADACHE

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CGRP as the target of new migraine therapies — successful translation from bench to clinic

(2018) Lars Edvinsson et al.   Nature Reviews Neurology

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

(2018) Vladimir Skljarevski et al.   JAMA Neurology

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

(2018) Angelo Camporeale et al.   BMC Neurology

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Side effects associated with current and prospective antimigraine pharmacotherapies

(2017) Abimael González-Hernández et al.   Expert Opinion on Drug Metabolism & Toxicology

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines

(2017) Joshua M. Cohen et al.   HEADACHE

Blocking CGRP in migraine patients – a review of pros and cons

(2017) Marie Deen et al.   JOURNAL OF HEADACHE AND PAIN

Challenging chronic migraine: targeting the CGRP receptor

(2017) Maria Adele Giamberardino et al.   LANCET NEUROLOGY

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Anti-CGRP antibodies block CGRP-induced diarrhea in mice

(2017) Eric A. Kaiser et al.   NEUROPEPTIDES

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Update on the Pharmacological Treatment of Chronic Migraine

(2016) Christina Sun-Edelstein et al.   Current Pain and Headache Reports

Impact of migraine on fibromyalgia symptoms

(2016) Maria Adele Giamberardino et al.   JOURNAL OF HEADACHE AND PAIN

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Wiping Out CGRP: Potential Cardiovascular Risks

(2016) Antoinette MaassenVanDenBrink et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Comment on “A second trigeminal CGRP receptor: function and expression of the AMY1 receptor”

(2016) Kristian Agmund Haanes et al.   Annals of Clinical and Translational Neurology

A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation

(2015) K Hoehlig et al.   BRITISH JOURNAL OF PHARMACOLOGY

Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention

(2015) Richard B. Lipton et al.   HEADACHE

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

The diagnosis and treatment of chronic migraine

(2015) Mark W. Weatherall   Therapeutic Advances in Chronic Disease

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

(2014) Marcelo E Bigal et al.   CEPHALALGIA

An Ongoing Role of α-Calcitonin Gene–Related Peptide as Part of a Protective Network Against Hypertension, Vascular Hypertrophy, and Oxidative Stress

(2014) Sarah-Jane Smillie et al.   HYPERTENSION

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Calcitonin gene-related peptide protects the myocardium from ischemia induced by endothelin-1: Intravital microscopic observation and 31P-MR spectroscopic studies

(2014) Satoshi Homma et al.   LIFE SCIENCES

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

(2014) T. W. Ho et al.   NEUROLOGY

Calcitonin Gene-Related Peptide: Physiology and Pathophysiology

(2014) F. A. Russell et al.   PHYSIOLOGICAL REVIEWS

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

(2013) Marcelo E Bigal et al.   CEPHALALGIA

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

(2013) Ronald Marcus et al.   CEPHALALGIA

Calcitonin-gene related peptide and cerebral vasospasm

(2013) Karl-Michael Schebesch et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain

(2013) Rodrigo Noseda et al.   PAIN

Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF

(2012) Jan Hoffmann et al.   CEPHALALGIA

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

(2011) David J Hewitt et al.   CEPHALALGIA

Chemical Mediators of Migraine: Preclinical and Clinical Observations

(2011) Saurabh Gupta et al.   HEADACHE

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study

(2010) Hans-Christoph Diener et al.   CEPHALALGIA

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

(2010) Jakob Møller Hansen et al.   CEPHALALGIA

Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers

(2010) M. S. Asghar et al.   NEUROLOGY

Effect of Adrenomedullin on the Cerebral Circulation: Relevance to Primary Headache Disorders

(2009) KA Petersen et al.   CEPHALALGIA

Elevated Saliva Calcitonin Gene-Related Peptide Levels During Acute Migraine Predict Therapeutic Response to Rizatriptan

(2009) Roger K. Cady et al.   HEADACHE

Preventive Migraine Treatment

(2009) Stephen D. Silberstein   NEUROLOGIC CLINICS

The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs

(2009) Carlos M. Villalón et al.   PHARMACOLOGY & THERAPEUTICS